Literature DB >> 30798507

The Neuroprotective Effect of Doxycycline on Neurodegenerative Diseases.

Flávia Viana Santa-Cecília1, Caio Abner Leite2, Elaine Del-Bel3,4, Rita Raisman-Vozari5.   

Abstract

Neurodegenerative diseases (NDs) are a group of chronic, progressive disorders characterized by the gradual loss of neurons that affect specific regions of the brain, which leads to deficits in specific functions (e.g., memory, movement, cognition). The mechanism that drives chronic progression of NDs remains elusive. Among the proposed underlying pathophysiological mechanisms, aggregation and accumulation of misfolded proteins and neuroinflammation have been credited to contribute to extensive neural loss. Therapeutic agents that confer neuroprotection by downregulating these shared characteristics could therefore have beneficial effects on a wide range of NDs. In this regard, a commonly used antibiotic, doxycycline (Doxy), has been shown to reduce the progression and severity of disease in different experimental models of neurodegeneration by counteracting these common features. This review will focus on the effects reported for Doxy regarding its neuroprotective properties, the "off-target" effects, thereby supporting its evaluation as a new therapeutic approach for diseases associated with a neurodegeneration.

Entities:  

Keywords:  Doxycycline; Less neurons; Misfolded proteins; Neurodegeneration; Neuroinflammation

Mesh:

Substances:

Year:  2019        PMID: 30798507     DOI: 10.1007/s12640-019-00015-z

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  8 in total

1.  Doxycycline vs Placebo at 12 Weeks in Patients With Mild Thyroid-Associated Ophthalmopathy: A Randomized Clinical Trial.

Authors:  Yuan Pan; Yu-Xi Chen; Jian Zhang; Miao-Li Lin; Guang-Ming Liu; Xue-Liang Xu; Xian-Qun Fan; Yong Zhong; Qing Li; Si-Ming Ai; Wen Xu; Jia Tan; Hui-Fang Zhou; Dong-Dong Xu; Hui-Ying Zhang; Bei Xu; Sha Wang; Jun-Jie Ma; Shuo Zhang; Lin-Yang Gan; Jian-Tao Cui; Li Li; Yan-Yan Xie; Xinxing Guo; Nathan Pan-Doh; Zhuo-Ting Zhu; Yao Lu; Yu-Xun Shi; Yi-Wen Xia; Zuo-Yi Li; Dan Liang
Journal:  JAMA Ophthalmol       Date:  2022-09-29       Impact factor: 8.253

Review 2.  Challenges of repurposing tetracyclines for the treatment of Alzheimer's and Parkinson's disease.

Authors:  Iva Markulin; Marija Matasin; Viktorija Erdeljic Turk; Melita Salković-Petrisic
Journal:  J Neural Transm (Vienna)       Date:  2022-01-04       Impact factor: 3.850

3.  Tetracycline derivatives reduce binge alcohol consumption in High Drinking in the Dark mice.

Authors:  John C Crabbe; Angela R Ozburn; Robert J Hitzemann; Stephanie E Spence; Wyatt R Hack; Jason P Schlumbohm; Pamela Metten
Journal:  Brain Behav Immun Health       Date:  2020-03-19

4.  UPRmt activation improves pathological alterations in cellular models of mitochondrial diseases.

Authors:  Juan M Suárez-Rivero; Carmen J Pastor-Maldonado; Suleva Povea-Cabello; Mónica Álvarez-Córdoba; Irene Villalón-García; Marta Talaverón-Rey; Alejandra Suárez-Carrillo; Manuel Munuera-Cabeza; Diana Reche-López; Paula Cilleros-Holgado; Rocío Piñero-Perez; José A Sánchez-Alcázar
Journal:  Orphanet J Rare Dis       Date:  2022-05-17       Impact factor: 4.303

5.  Synergistic toxicity in an in vivo model of neurodegeneration through the co-expression of human TDP-43M337V and tauT175D protein.

Authors:  Alexander J Moszczynski; Madeline Harvey; Niveen Fulcher; Cleusa de Oliveira; Patrick McCunn; Neil Donison; Robert Bartha; Susanne Schmid; Michael J Strong; Kathryn Volkening
Journal:  Acta Neuropathol Commun       Date:  2019-11-08       Impact factor: 7.801

Review 6.  The Gut-Brain Axis and Its Relation to Parkinson's Disease: A Review.

Authors:  Emily M Klann; Upuli Dissanayake; Anjela Gurrala; Matthew Farrer; Aparna Wagle Shukla; Adolfo Ramirez-Zamora; Volker Mai; Vinata Vedam-Mai
Journal:  Front Aging Neurosci       Date:  2022-01-07       Impact factor: 5.750

7.  The effect of doxycycline on neuron-specific enolase in patients with traumatic brain injury: a randomized controlled trial.

Authors:  Noha O Mansour; Mohamed A Shama; Rehab H Werida
Journal:  Ther Adv Chronic Dis       Date:  2021-06-23       Impact factor: 5.091

8.  Doxycycline rescues recognition memory and circadian motor rhythmicity but does not prevent terminal disease in fatal familial insomnia mice.

Authors:  Giada Lavigna; Antonio Masone; Ihssane Bouybayoune; Ilaria Bertani; Jacopo Lucchetti; Marco Gobbi; Luca Porcu; Stefano Zordan; Mara Rigamonti; Luca Imeri; Elena Restelli; Roberto Chiesa
Journal:  Neurobiol Dis       Date:  2021-08-04       Impact factor: 5.996

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.